KPTI
Karyopharm Therapeutics Inc
Halal Rating :
Last Price
$0.67
Last updated:
Market Cap
-
7D Change
-1.16%
1 Year Change
-20.03%
Company Overview
Industries
Exchange
Next Earnings Date
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company's lead product, XPOVIO® (selinexor), is an oral Selective Inhibitor of Nuclear Export (SINE) compound used in the treatment of multiple myeloma and diffuse large B-cell lymphoma.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $38.78m | $76.45m | - | $11.38m | 0.00% | 14.89% |
| June 30, 2024 | $42.79m | $35.15m | - | $-35753000.0 | 0.00% | 101.71% |
| March 31, 2024 | $33.13m | $72.77m | - | $5.88m | 0.00% | 8.09% |
Company Impact
Help us evaluate Karyopharm Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.